BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 19657711)

  • 1. Clinicopathological characteristics of triple-negative breast cancers.
    Sasaki Y; Tsuda H
    Breast Cancer; 2009; 16(4):254-9. PubMed ID: 19657711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frequently increased epidermal growth factor receptor (EGFR) copy numbers and decreased BRCA1 mRNA expression in Japanese triple-negative breast cancers.
    Toyama T; Yamashita H; Kondo N; Okuda K; Takahashi S; Sasaki H; Sugiura H; Iwase H; Fujii Y
    BMC Cancer; 2008 Oct; 8():309. PubMed ID: 18950515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
    Diaz LK; Cryns VL; Symmans WF; Sneige N
    Adv Anat Pathol; 2007 Nov; 14(6):419-30. PubMed ID: 18049131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple negative breast cancer: clinicopathological characteristics and treatment strategies.
    Akiyama F; Iwase H
    Breast Cancer; 2009; 16(4):252-3. PubMed ID: 19506994
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of basal-like subtype in triple-negative breast cancer.
    Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
    Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Triple-negative breast cancer: histological subtypes and immunohistochemical and clinicopathological features.
    Ishikawa Y; Horiguchi J; Toya H; Nakajima H; Hayashi M; Tagaya N; Takeyoshi I; Oyama T
    Cancer Sci; 2011 Mar; 102(3):656-62. PubMed ID: 21214677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Morphological characteristics of basal-like subtype of breast carcinoma with special reference to cytopathological features.
    Ishihara A; Tsuda H; Kitagawa K; Yoneda M; Shiraishi T
    Breast Cancer; 2009; 16(3):179-85. PubMed ID: 19466513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple-negative breast carcinoma in women from Vietnam and the United States: characterization of differential marker expression by tissue microarray.
    Williams DJ; Cohen C; To TV; Page AJ; Lawson D; Sussman ZM; Nassar A
    Hum Pathol; 2009 Aug; 40(8):1176-81. PubMed ID: 19368951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What is the difference between triple-negative and basal breast cancers?
    Seal MD; Chia SK
    Cancer J; 2010; 16(1):12-6. PubMed ID: 20164685
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytologic features of triple-negative breast carcinoma.
    Bonzanini M; Morelli L; Bonandini EM; Leonardi E; Pertile R; Dalla Palma P
    Cancer Cytopathol; 2012 Dec; 120(6):401-9. PubMed ID: 22833438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. "Targeting" triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.
    Nanda R
    Semin Oncol; 2011 Apr; 38(2):254-62. PubMed ID: 21421115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triple-negative breast cancer: risk factors to potential targets.
    Schneider BP; Winer EP; Foulkes WD; Garber J; Perou CM; Richardson A; Sledge GW; Carey LA
    Clin Cancer Res; 2008 Dec; 14(24):8010-8. PubMed ID: 19088017
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Triple-negative breast cancer types exhibit a distinct poor clinical characteristic in lymph node-negative Chinese patients.
    Liu ZB; Liu GY; Yang WT; Di GH; Lu JS; Shen KW; Shen ZZ; Shao ZM; Wu J
    Oncol Rep; 2008 Oct; 20(4):987-94. PubMed ID: 18813844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA copy number alterations and expression of relevant genes in triple-negative breast cancer.
    Han W; Jung EM; Cho J; Lee JW; Hwang KT; Yang SJ; Kang JJ; Bae JY; Jeon YK; Park IA; Nicolau M; Jeffrey SS; Noh DY
    Genes Chromosomes Cancer; 2008 Jun; 47(6):490-9. PubMed ID: 18314908
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metaplastic breast carcinomas and their relationship with basal-like phenotype.
    Cakir A; Gönül II; Uluoğlu O
    Turk Patoloji Derg; 2012; 28(2):134-41. PubMed ID: 22627631
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy of triple-negative breast cancer.
    Arslan C; Dizdar O; Altundag K
    Expert Opin Pharmacother; 2009 Sep; 10(13):2081-93. PubMed ID: 19640211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Triple-negative breast carcinoma--rewiev of current literature].
    Rubovszky G; Udvarhelyi N; Horváth Z; Láng I; Kásler M
    Magy Onkol; 2010 Dec; 54(4):325-35. PubMed ID: 21163763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sporadic invasive breast carcinomas with medullary features display a basal-like phenotype: an immunohistochemical and gene amplification study.
    Rodríguez-Pinilla SM; Rodríguez-Gil Y; Moreno-Bueno G; Sarrió D; Martín-Guijarro Mdel C; Hernandez L; Palacios J
    Am J Surg Pathol; 2007 Apr; 31(4):501-8. PubMed ID: 17414096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Breast carcinomas expressing basal markers have poor clinical outcome regardless of estrogen receptor status.
    Shin BK; Lee Y; Lee JB; Kim HK; Lee JB; Cho SJ; Kim A
    Oncol Rep; 2008 Mar; 19(3):617-25. PubMed ID: 18288392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Biological features of breast cancer in patients under 35].
    Damenia AO; Turkevich EA; Semiglazov VF; Kochetova IA; Gurbanov SS; Bit-Sava EM; Efimenko AV
    Vopr Onkol; 2007; 53(6):674-6. PubMed ID: 18416136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.